Protein profiling reveals new prostate cancer mechanisms

A study by the University of Tampere in Finland used protein profiling to find new prostate cancer mechanisms that are not shown by aberrations at the genomic level. Several new potential biomarkers of prostate cancer were also found.

Genes that affect prostate cancer evolution have been studied for a long time. However, changes in the protein levels are not well known.

The Center for Prostate Cancer Research and the Center for Proteomics and Personalized Medicine at the University of Tampere cooperated to profile the protein expression of prostate cancer by using mass spectrometry for the first time. The researchers compared protein expression to genomic and messenger RNAs in the same samples.

The result was that the changes in gene copy numbers and DNA methylation largely explain messenger RNA expression but not the changes on the protein level. The association between messenger RNA expression and protein levels was also weak. The study thus uncovered such mechanisms of prostate cancer that are not indicated by the alterations at the genomic level.

"In particular, changes in the citric acid cycle emerged in our analyzes," Adjunct Professor Leena Latonen says.

"The results enable exploring the significance of these changes," Latonen continues.

In addition to the disease mechanisms, protein profiling revealed several potential new biomarkers.

According to Professor Tapio Visakorpi, biomarkers able to recognize the aggressive forms of prostate cancer would be especially useful. That is one of the aspects on which the researchers will focus next.​​

Source: http://www.uta.fi/en/news/story/proteins-reveal-new-mechanisms-prostate-cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop new approach to predict immunotherapy response in breast cancer patients